Akari Therapeutics Plc Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2023 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Akari Therapeutics Plc quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2023 to Q2 2024.
  • Akari Therapeutics Plc Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $0.000, a 100% decline year-over-year.
  • Akari Therapeutics Plc annual Share-based Payment Arrangement, Expense for 2023 was $275K, a 50.8% decline from 2022.
  • Akari Therapeutics Plc annual Share-based Payment Arrangement, Expense for 2022 was $560K, a 78% increase from 2021.
  • Akari Therapeutics Plc annual Share-based Payment Arrangement, Expense for 2021 was $315K, a 3.34% decline from 2020.
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $0 -$133K -100% Apr 1, 2024 Jun 30, 2024 8-K 2024-09-06
Q1 2024 $296K +$31K +11.7% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q2 2023 $133K Apr 1, 2023 Jun 30, 2023 8-K 2024-09-06
Q1 2023 $265K Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.